The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

1. Clinically significant renal dysfunction defined as a serum creatinine concentration \>1.4 mg/dL (females) or \>1.6 mg/dL (males) or a blood urea nitrogen concentration \>45 mg/dL at screening.

2. Use of any of the following medications:

1. Metformin

2. Combination drugs that include Metformin

3. Sildenafil

4. Tadalafil

5. Vardenafil

6. Pioglitazone

7. Rosiglitazone

8. Short acting insulins

9. An alpha blocker

10. Oral nitrates

11. Medications associated with increased hepatic steatosis

12. Insulins

13. OCT2/MATE inhibitors (e.g. cimetidine, quinidine, and pyrimethamine)

* Methotrexate

* Tamoxifen

* Corticosteroids (Nasal steroids are allowed if the subject has been on a stable dose for the past 12 weeks and the dose employed does not exceed the maximal recommended dose.)

* Estrogens

* Amiodarone

* Valproic acid

* Coumadin

* Isoniazide

* Nucleoside analogues used for the treatment of HIV infections

14. Any dietary supplement other than multi-vitamins

3. Evidence of significant alcohol consumption (defined as \>7 drinks/week for females and \>14 drinks/week for males) within 6 months prior to randomization or presence or suspicion of other forms of chronic liver disease (e.g., cirrhosis, autoimmune hepatitis (\>1:160 ANA), Wilson's disease, Hemochromatosis (Ferritin \>1000 ug/L and percent iron saturation \>45%), hepatitis A, B or C)

4. Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

1. Unable to undergo MRI or contraindications for MRI procedure

2. History of cardio- or cerebro-vascular disease event within the previous 6 months

3. Requires anti-coagulation therapy

4. Gastrointestinal disorders including, but not limited to, the following: pancreatitis, inflammatory bowel disease, or other diseases associated with malabsorption or persistent abdominal discomfort

5. Endocrine disorders other than type 2 diabetes and hypothyroidism on stable replacement therapy

6. Chronic infection (e.g., tuberculosis, human immunodeficiency virus infection, hepatitis A virus, hepatitis B virus, or hepatitis C virus)

7. Neurological or psychiatric diseases that preclude valid execution of informed consent or may interfere with the subject's compliance with study procedures (e.g., major depressive disorder within the last 2 years, a history of suicidal behavior in the last 3 months)

8. History of other psychiatric disorders including schizophrenia and bipolar disorder)

5. Participation in a weight loss program within the past 3 months.

6. Weight change ≥5% during the past month.

7. History of substance abuse (including alcohol abuse as defined above) in the past 3 months or a positive screen for drugs of abuse or alcohol at screening.

8. Has received any investigational drug within 3 months of Screening.

9. Has donated blood within 3 months before Screening or is planning to donate blood during the study.

10. Has had a serious infection, such as pneumonia in the previous 12 weeks

11. Has known allergies or hypersensitivity to metformin, sildenafil or leucine

12. Is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or NuSirt Biopharma.

13. Is employed by NuSirt Biopharma (defined as an employee, temporary contract worker, or designee responsible for the conduct of the study).

\-

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

What this study is about

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

What this study is about